AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2 , with an EC 50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1 , 3, 4, 5, 6, 7, and 8 subtypes.
Storage Temp
Store at -80°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description
AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2 , with an EC 50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1 , 3, 4, 5, 6, 7, and 8 subtypes.
In Vitro
AZD-8529 potentiates the effects of glutamate at mGluR2 with an EC 50 of 195 nM. AZD-8529 does not elicit antagonist responses on mGluRs at 25 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
AZD-8529 (0.3-mg/kg, i.m.) reduces nicotine priming-induced and cue-induced reinstatement in squirrel monkeys . AZD-8529 (30 mg/kg; i.p.) decreases the increased extracellular dopamine induced by nicotine in accumbens shell of freely-moving rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague-Dawley rats Dosage: 10 mg/kg, 30 mg/kg Administration: Intraperitoneal injection; 2 hours before nicotine injections Result: Decreased the increased extracellular dopamine induced by nicotine (0.4 mg/kg, s.c.) in accumbens shell of freely-moving rats.
